About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT01342939

Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)

The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In sulphonyl urea treated subj...

Lead sponsor: University Hospital, Gentofte, Copenhagen•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital, Gentofte, Copenhagen

Collaborators

University of Copenhagen
Steno Diabetes Center Copenhagen

Comparison of of insulin secretion (AUC) during the experimental days. Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Caucasians above 18 years
•BMI \> 19 kg/m2
•Negative pancreatic beta cell- and glutamate decarboxylase-65(GAD65)- autoantibodies
•Normal haemoglobin
•Normal bloodpressure
•Informed concent

Exclusion Criteria

•Known liver disease or affected liver enzymes (ALAT/ASAT \>2 x upper normal limit)
•Nephropathy (see creatinine\> 130 μM and / or albuminuria)
•Treatment with medications that cannot be discontinued for 12 hours
•Any condition that the investigators feel would interfere with trial participation
•Pregnancy or lactation

Related studies

Impact of SGLT2 on Glucosuria in HNF1A-MODY

NCT05417646 · Maturity-Onset Diabetes of the Young, Type 3, Type 2 Diabetes

Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE

NCT03607604 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, and more

Genetic Causes of Gestational Diabetes in the Emirati Population

NCT03589092 · Gestational Diabetes, GDM, and more

Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes

NCT04239586 · Maturity-Onset Diabetes of the Young, Type 3, Maturity Onset Diabetes of the Young, Type 1, and more

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

NCT03081676 · Maturity-Onset Diabetes of the Young, Type 3

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 15, 2013Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment31

Start dateJan 2011

Last updatedJan 15, 2013

Condition

Maturity-onset Diabetes of the Young

Locations shown

Diabetes Research Division, Gentofte University Hospital, Niels Andersens vej 65, opgang 40, 2.

Hellerup

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2013Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions